Briefs: Piramal Enterprises and Shilpa Medicare
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
Shilpa Medicare Ltd's finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The joint venture will help both the parties to further develop the high-margin service business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
40,000 visitors and representatives of more than 80 countries set to visit the show
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
The only definitive way to diagnose and stage lung cancers is through biopsies
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
Total investment envisaged in this project stands at up to Rs 70 crore
Government of India has granted a patent for invention entitled "An improved safe process for the preparation of Sartan drugs of Formula I".
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Subscribe To Our Newsletter & Stay Updated